Management of extrapulmonary sarcoidosis: challenges and solutions

Khalid Al-Kofahi,1,* Peter Korsten,2,3* Christian Ascoli,3 Shanti Virupannavar,4 Mehdi Mirsaedi,5 Ian Chang,6 Naim Qaqish,7 Lesley A Saketkoo,8 Robert P Baughman,9 Nadera J Sweiss3,4
1 Department of Molecular Biosciences, University of Kansas, Lawrence, KS, USA; 2 Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany; 3 Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, IL; 4 Division of Rheumatology, University of Illinois at Chicago, Chicago, IL; 5 Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami Miller School of Medicine, Miami, FL; 6 Department of Medicine, Michigan State University College of Osteopathic Medicine, East Lansing, MI; 7 Department of Gastroenterology, Hepatology and Nutrition, University of Buffalo, Buffalo, NY; 8 New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Sciences Center, New Orleans, LA; 9 Department of Medicine, University Medical Center of Cincinnati, Cincinnati, OH, USA

*These authors contributed equally to this work

Correspondence: Nadera J Sweiss
Division of Pulmonary, Critical Care, Sleep and Allergy, and Division of Rheumatology, University of Illinois at Chicago, Chicago, IL, USA 60612, USA
Tel +1 312 413 4244
Fax +1 312 996 3896
Email nsweiss@uic.edu

This article was published in the following Dove Press journal:
Therapeutics and Clinical Risk Management
7 November 2016
Number of times this article has been viewed

Background: Sarcoidosis is a chronic multisystem disease of unknown etiology characterized by noncaseating granulomas that most often involves the lungs, but frequently has extrapulmonary manifestations, which might be difficult to treat in individual patients.

Objective: To review different disease manifestations, focusing on extrapulmonary organ systems, and to provide treatment options for refractory cases.

Materials and methods: We performed a literature search using Medline and Google Scholar for individual or combined keywords of “sarcoidosis, extrapulmonary, treatment, kidney, neu- rosomal sarcoidosis, cardiovascular, gastrointestinal, transplantation, musculoskeletal, rheumatology, arthritis, and skin”. Peer-reviewed articles, including review articles, clinical trials, observational trials, and case reports that were published in English were included. References from retrieved articles were also manually searched for relevant articles.

Results and conclusion: Isolated involvement of a single organ or organ system is rare in sarcoidosis, and thus all patients must be thoroughly evaluated for additional disease manifestations. Cardiac sarcoidosis and neurosarcoidosis may be life-threatening. Clinicians need to assess patients comprehensively using clinical, laboratory, imaging, and histopathological data to recommend competently the best and least toxic treatment option for the individual patient.

Keywords: sarcoidosis, immunosuppressive agents, chronic granulomatous diseases, diagnostic tests

Introduction

“Sarcoidosis would be a benign and relatively unimportant disease but for three troublesome complications: pulmonary fibrosis, fibrotic uveitis, and nephrocalcinosis.” This notion by James et al,1 published in the Lancet in 1967, illustrates that physicians treating sarcoidosis have been aware of its frequent extrapulmonary disease manifestations for decades. Sarcoidosis is a chronic inflammatory disorder of unknown etiology, characterized by noncaseating granulomas involving the lungs in more than 90% of patients.2 Ocular, lymph-node, and cutaneous manifestations are next in frequency, but any organ system can be affected.3 Extrapulmonary disease manifestations contribute to significant morbidity, but can easily be missed. The ACCESS study revealed that 50% of the 736 sarcoidosis patients studied had pulmonary sarcoidosis and coexisting extrapulmonary sarcoidosis compared to only 2% of patients who presented with isolated extrapulmonary disease.3 Prevalence of extrapulmonary sarcoidosis was higher among African-Americans in comparison to Caucasians.3 Remission may occur in nearly two-thirds of patients after 1–2 years; still, up to a third of patients will have chronic or progressive disease.4

The diagnosis requires exclusion of other etiologies, and relies on compatible history, clinical findings, and noncaseating granulomas on histology. In patients with...
normal chest radiographs, evaluation and monitoring of extrapulmonary sarcoidosis with other diagnostic modalities, including ultrasound, chest computed tomography, gallium scintigraphy, magnetic resonance imaging (MRI), and positron-emission tomography (PET), can be helpful.

Despite the lack of evidence-based studies, glucocorticosteroids (GCs), namely prednisone, are the first-line therapy of sarcoidosis. Recommended starting doses vary between 20 and 40 mg/day, and are tapered slowly to a maintenance dose of less than 10 mg/day as the disease allows. However, lack of response or drug toxicity are limiting factors, especially with long-term treatment, and can result in significant disability. GC-sparing drugs, such as disease-modifying antirheumatic drugs or biological agents, are increasingly used in these instances. Clinicians are increasingly initiating methotrexate (MTX) along with GCs in clinical profiles that portend a poor prognosis.

Extrapulmonary disease manifestations

This review focuses on cutaneous, renal, central nervous system (CNS), cardiac, gastrointestinal, and musculoskeletal manifestations, though other organ systems not covered in this review can be involved. The following sections include the estimated frequencies, clinical presentation, relevant diagnostic tests, and management recommendations for the respective organ systems based on the current available evidence and the authors’ experience. Figure 1 gives an overview of the reported frequencies of manifestations of extrapulmonary sarcoidosis.

**Cutaneous sarcoidosis**

Cutaneous lesions occur in 9%–37% of patients with extrapulmonary sarcoidosis. Both specific skin lesions with the presence of granulomas and nonspecific skin lesions lacking granulomatous inflammation can be histologically detected in sarcoidosis. One study found that 20.5% of 170 patients with sarcoidosis had erythema nodosum (EN), a nonspecific skin lesion lacking granulomas, as the most common skin manifestation. Also detected were skin plaques (4.3%), subcutaneous nodules (4.3%), maculopapular eruptions (3.7%), scar lesions (2.9%), psoriasiform plaques (0.9%), and lupus pernio (2.7%). The last, an indolent violaceous skin lesion affecting the face, had a higher association with...
pulmonary disease when compared to patients with EN or other lesions. Cutaneous sarcoidosis has also been documented to develop in scars and tattoos. The presence of EN is frequently found in Löfgren’s syndrome, the acute form of sarcoidosis with bilateral hilar lymphadenopathy and ankle (peri)arthritis, and usually portends a good prognosis. In addition, scarring and nonscarring alopecia, as well as nail changes (such as onycholysis, dystrophy, hyperkeratosis, and longitudinal ridging) may occur. Interestingly, nail changes seem to indicate bone involvement, and appropriate workup should therefore be considered. The World Association of Sarcoidosis and Other Granulomatous Diseases has proposed various end points for cutaneous sarcoidosis to be assessed in clinical trials (Physician Global Assessment, Sarcoidosis Activity and Severity Index, Lupus Pernio Activity and Severity Index, photographs, lesion counts, and skin biopsies).

Treatment of cutaneous sarcoidosis
Cutaneous lesions are treated only if they cause significant cosmetic disfigurement, psychological effects, or if the lesions are uncontrollable. Local GC therapy, with intralvesional injections for thick plaque lesions, is first-line treatment. Triamcinolone acetonide has reasonable availability, potency, and duration of action. Patients with progressive lesions will nevertheless require systemic therapy, most often GCs or hydroxychloroquine. Cases of lupus pernio achieved considerable improvement with halobetasol propionate 0.05% ointment twice daily for 10 weeks. Mild improvements were seen in 72% of 54 patients, and near or complete resolution was observed in 20% with systemic GCs. Antimalarials, antibiotics (tetracyclines, antimycobacterials), and immunosuppressive agents (MTX, thalidomide, apremilast, tumor necrosis factor alpha (TNFα) antagonists, such as infliximab and adalimumab, among others) have been investigated with variable success in refractory cases.

Renal involvement
Although isolated renal involvement represents less than 5% of extrapulmonary sarcoidosis, the rate of renal involvement throughout the disease course is probably much higher. Sarcoidosis can involve the kidneys in three different ways: 1) hypercalcemia, which precedes the development of hypercalcemia, occurring in 50% and 10%, respectively, as a result of calcitriol-producing granulomatous burden, which may overwhelm the kidneys’ regulatory mechanisms and progress to renal insufficiency; 2) tubulo-interstitial nephritis with or without granulomatous involvement; and 3) nephrocalcinosis and/or nephrolithiasis, which can occur as a result of hypercalcemia. These can occur independently or less frequently in combination. Co-occurrence with other renal disease, primarily IgA nephropathy, is not uncommon. Although sarcoidosis-associated end-stage renal disease is very uncommon and more likely due to other causes, a significant degree of renal insufficiency was common in one retrospective series, and hypercalcemia might be a contributing factor. Moreover, relapses may occur in up to a quarter of patients who undergo kidney transplantation because of sarcoidosis and may negatively impact graft survival.

One cohort study revealed that up to 3.6% of sarcoidosis cases had nephrolithiasis at first visit, and another 2.7% of these patients were asymptomatic. Therefore, sarcoidosis should be considered if no other cause of nephrolithiasis is identified. Rare presentations include pseudotumors or mechanical complications, such as hydronephrosis, if retroperitoneal structures are affected by granulomatous inflammation.

All patients diagnosed with sarcoidosis should be evaluated for the presence of renal involvement to prevent significant chronic kidney disease. Workup includes serum creatinine, blood urea nitrogen, estimated glomerular filtration rate, protein and calcium in both serum and urine, and screening of the urinary sediment for casts of red or white blood cells. 25-hydroxyvitamin D₃, 1,25-dihydroxyvitamin D₃, and parathyroid hormone should be measured in patients with hypercalcemia or hypercalciiuria to assess the degree and cause of calcium dysregulation. Renal biopsy remains the gold standard to confirm renal sarcoidosis. Nevertheless, histological findings are not specific for sarcoidosis, requiring infection and drug hypersensitivity to be excluded, as these are more frequent causes of interstitial nephritis.

Treatment of renal sarcoidosis
GCs are the mainstay of treatment in interstitial nephritis, and are often very effective. They have also been used successfully in hypercalcemia and hypercalciuria, although many times discontinuation of vitamin D supplements is sufficient to normalize calcium levels. When GCs fail, ketoconazole or hydroxychloroquine have been used successfully in such cases. Additional immunosuppressive agents, such as azathioprine (AZA) or mycophenolate mofetil, have (albeit rarely) also been used in cases of granulomatous interstitial nephritis not responding to GCs.

The long-term prognosis of renal sarcoidosis seems to correlate with response to therapy after 1 month of treatment and
inversely with the initial fibrosis score on histopathological examination. In refractory renal sarcoidosis or failure of treatment leading to end-stage renal disease, renal transplantation is an option. Recurrence of sarcoidosis in transplanted kidneys has been reported and requires close surveillance, as is necessary in other diseases. Relapse after transplantation has been managed with infliximab in a steroid-resistant case.

Neurosarcoidosis

Involvement of the CNS or peripheral nervous system is present in 5%–15% of cases, and represents one of the more serious complications of sarcoidosis. Postmortem studies indicate that isolated neurosarcoidosis occurs in 3%–17% of cases and that subclinical neurosarcoidosis may be more prevalent but underdiagnosed, with a rate of antemortem diagnosis of 35%–50% of cases. Symptoms relating to involvement of the cranial nerves, hypothalamus, or pituitary glands have been reported to be the initial clinical manifestation in up to 50%–70% of neurosarcoidosis cases. These can be present simultaneously in up to a third of patients or be isolated manifestations. A biopsy of the CNS is required for a definitive diagnosis, especially in isolated cases. However, in cases with biopsy-proven sarcoidosis of other sites, the diagnosis can be made without a CNS biopsy. The WASOG criteria for neurosarcoidosis are shown in Table 1.

Table 1 The WASOG organ-assessment tool for neurosarcoidosis

<table>
<thead>
<tr>
<th>WASOG organ-assessment tool</th>
<th>Clinical Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Highly probable</strong></td>
<td>Clinical syndrome consistent with granulomatous inflammation of the meninges, brain, ventricular (CSF) system, cranial nerves, pituitary gland, spinal cord, cerebral vasculature, or nerve roots plus An abnormal MRI characteristic of neurosarcoidosis, defined as exhibiting abnormal enhancement following the administration of gadolinium or a CSF exam demonstrating inflammation</td>
</tr>
<tr>
<td><strong>At least probable</strong></td>
<td>Isolated facial palsy, negative MRI Clinical syndrome consistent with granulomatous inflammation of the meninges, brain, ventricular (CSF) system, cranial nerves, pituitary gland, spinal cord, cerebral vasculature, or nerve roots, but without characteristic cMRI or CSF findings</td>
</tr>
<tr>
<td><strong>Possible</strong></td>
<td>Seizures, negative MRI Cognitive decline, negative MRI</td>
</tr>
<tr>
<td><strong>No consensus</strong></td>
<td>Peripheral neuropathy involving large fibers (including axonal and demyelinating polyneuropathies and multiple mononeuropathies) Cranial nerve palsies other than VII, negative MRI Pleocytosis in the CSF Low CSF glucose</td>
</tr>
</tbody>
</table>

small-nerve fibers are not done routinely in all sarcoidosis patients. If collected carefully, skin-punch biopsy is helpful in diagnosing SFN by showing lower intraepidermal nerve-fiber density.\(^{56}\)

A definitive diagnosis of neurosarcoidosis is challenging, due to the difficulty of obtaining biopsies without causing any damage. Therefore, brain MRI is considered the most sensitive noninvasive test for neurosarcoidosis, but lacks specificity.\(^{45}\) Lumbar punctures are reported to be normal in up to a third of patients, pathologic cerebrospinal fluid (CSF) findings include mild pleocytosis, increased protein levels, and mild hypoglycorrhachia, which are similar to those seen in multiple sclerosis or systemic lupus erythematosus.\(^{45}\) Additionally, the usefulness of CSF angiotensin-converting enzyme (ACE) levels is still a matter of debate, because it can also be found in conditions other than sarcoidosis.\(^{45,57,58}\)

### Treatment of neurosarcoidosis

Patients with confirmed systemic sarcoidosis and testing suggestive of CNS involvement should be treated immediately, due to the potentially high morbidity and mortality of neurosarcoidosis. GCs are first-line treatment, with a typical initial dose of 1 mg/kg/day. Severe cases may warrant a pulse of methylprednisolone at doses of 500–1,000 mg/day for 3 consecutive days and subsequent oral tapering. Alternative treatments, such as MTX, AZA, cyclosporine A (CsA), and cyclophosphamide (CYC), have been successfully used in refractory disease or when adverse effects to GCs are significant, but this is based on experience rather than evidence.\(^{59}\) The response rate to MTX in neurosarcoidosis is nearly 60%, similar to that in pulmonary sarcoidosis.\(^{50}\) CsA was found to reduce the GC dose to 30%–58% of the initial stabilization dose, but nonetheless deterioration occurred in four of the six reported patients.\(^{61}\) The use of short-course pulse CYC given every 2–4 weeks demonstrated improvement of MRI or CSF abnormalities in seven of seven patients, and symptoms improved in four of seven and nine of ten patients in the respective studies.\(^{60,62}\) The dose used was initially 500 mg, then 750 mg for the second dose and a maintenance dose of 1 g given approximately every 3 weeks.\(^{60,62}\) Mycophenolate mofetil has been reported to be effective in CNS sarcoid, but not in sarcoid myopathy,\(^{63}\) but this case series was small, and firm conclusions cannot be drawn.\(^{63}\)

In corticosteroid-refractory disease or when rapid response is needed to avoid permanent disability, several case reports have indicated positive responses to infliximab.\(^{64}\) A review of 34 successful cases showed that 14 had improvement between the first and third infusions,\(^{64}\) and infliximab might be more effective than CYC.\(^{65}\) TNFα blockers also had positive effects on cognitive failure.\(^{52}\) One double-blind randomized controlled trial found a positive effect of ARA 290, an immunomodulating erythropoietin-derived compound, on symptoms of SFN in 22 patients.\(^{66}\) Lastly, radiation therapy with 20–25 Gy may be considered in patients who do not respond to drug therapy.\(^{67}\)

### Cardiac sarcoidosis

Cardiac sarcoidosis commonly coexists with systemic sarcoidosis, rather than as an isolated finding. The presence of oculocutaneous sarcoidosis with choroidal involvement has, for example, been suggested to reflect vascular endothelial dysfunction and coexist with cardiac disease, thus requiring evaluation for cardiac sarcoidosis.\(^{58}\)

The ethnic background of patients is of importance, since cardiac sarcoidosis has been reported much more frequently in Japanese patients (21%–58%) when compared to Caucasians or African-Americans (13%–25%) based on autopsy studies.\(^{69}\) There is a high rate of subclinical involvement, making overt cardiac sarcoidosis a rather rare manifestation.\(^{3}\)

Cardiac disease ranges from the incidental discovery in asymptomatic patients to life-threatening disease with sudden cardiac death. Patients commonly present with heart block, ventricular tachycardia/unsustained ventricular fibrillation, or heart failure due to cardiomyopathy.\(^{70}\)

History-taking is an essential element at both baseline and follow-up visits to detect symptoms that warrant further investigation.\(^{71}\) Any structural component, as well as any layer (endocardium [heart valves], myocardium, and pericardium) of the heart can be affected. Clinical symptoms will depend on the structures involved, and may include palpitations, syncope, shortness of breath, chest pain, or peripheral edema.\(^{69,72}\) With the widespread use of implantable cardioverter defibrillators (ICDs), the main causes of death in patients with cardiac sarcoidosis is progressive heart failure due to granulomatous infiltration of the myocardium, the latter accounting for 25% of deaths.\(^{73,74}\)

The possibility of cardiac sarcoidosis should be considered in: 1) adults under 55 years of age with new-onset electrocardiogram abnormalities, decreased systolic ejection fraction, or cardiac symptoms after excluding coronary artery disease; 2) adults under 55 years of age with sustained atrioventricular block (second or third degree); 3) patients of any age with sustained ventricular tachycardia and/or cardiomyopathy; and 4) all patients with diagnosed sarcoidosis of other sites.\(^{73,75,76}\) The different proposed diagnostic criteria for cardiac sarcoidosis are shown in Table 2.
Table 2 Criteria in use for the assessment of cardiac sarcoidosis

<table>
<thead>
<tr>
<th>WASOG organ-assessment tool</th>
<th>Expert-consensus recommendations on criteria for the diagnosis of cardiac sarcoidosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Highly probable</strong></td>
<td>1. Histological diagnosis from myocardial tissue cardiac sarcoidosis is performed in the presence of noncaseating granulomas on histological examination of myocardial tissue, with no alternative cause identified (including negative organismic stains if applicable)</td>
</tr>
<tr>
<td>N/A</td>
<td>2. Clinical diagnosis from invasive and noninvasive studies. It is probable that cardiac sarcoidosis is present if:</td>
</tr>
<tr>
<td>At least probable</td>
<td>a) there is histological diagnosis of extracardiac sarcoidosis, and</td>
</tr>
<tr>
<td></td>
<td>b) one or more of the following is present:</td>
</tr>
<tr>
<td></td>
<td>• corticosteroid-responsive and/or immunosuppressant-responsive cardiomyopathy or heart block</td>
</tr>
<tr>
<td></td>
<td>• unexplained reduced left ventricular ejection fraction (&lt;40%)</td>
</tr>
<tr>
<td></td>
<td>• unexplained sustained (spontaneous or induced) ventricular tachycardia</td>
</tr>
<tr>
<td></td>
<td>• Mobitz II second-degree heart block or third-degree heart block</td>
</tr>
<tr>
<td></td>
<td>• patchy uptake on dedicated cardiac positron-emission tomography</td>
</tr>
<tr>
<td></td>
<td>• delayed enhancement on cardiac magnetic resonance (CMR) imaging</td>
</tr>
<tr>
<td></td>
<td>• positive gallium uptake</td>
</tr>
<tr>
<td></td>
<td>• defect on perfusion scintigraphy or SPECT scan</td>
</tr>
<tr>
<td></td>
<td>• $T_2$ prolongation on CMR</td>
</tr>
<tr>
<td>Possible</td>
<td>• reduced left ventricular ejection fraction in the presence of other risk factors (eg, hypertension, diabetes mellitus)</td>
</tr>
<tr>
<td></td>
<td>• atrial dysrhythmias</td>
</tr>
<tr>
<td>No consensus</td>
<td>• frequent ectopia (~5% QRS complexes)</td>
</tr>
<tr>
<td></td>
<td>• bundle-branch block</td>
</tr>
<tr>
<td></td>
<td>• impaired right ventricular function with normal pulmonary vascular resistance</td>
</tr>
<tr>
<td></td>
<td>• fragmented QRS or pathologic Q waves in two or more anatomically contiguous leads</td>
</tr>
<tr>
<td></td>
<td>• at least one abnormal signal-averaged electrocardiogram</td>
</tr>
<tr>
<td></td>
<td>• interstitial fibrosis or monocyte infiltration</td>
</tr>
</tbody>
</table>


**Abbreviations:** SPECT, single-photon emission computed tomography; WASOG, World Association of Sarcoidosis and Other Granulomatous Diseases.

Workup commonly includes an electrocardiogram, 24-hour Holter monitoring and transthoracic echocardiography (TTE). The optimal diagnostic strategy still needs to be established; however, patients with cardiac sarcoidosis had significantly more abnormal Holter monitoring and TTE findings.71 The sensitivity and specificity for the detection of cardiac sarcoidosis by Holter monitoring were reported with 67% and 80%, respectively, making its usefulness controversial, but it is relatively inexpensive.77

TTE shows variable and nonspecific findings, including interventricular thinning, regional wall abnormalities, or aneurysmal distortion. These findings are similar to those found in ischemic heart disease; therefore, coronary angiography is recommended to exclude coronary artery disease.69

Over the last few years, other noninvasive imaging modalities have emerged and been tested in cardiac sarcoidosis. Cardiac MRI (CMR) and $^{18}$F-fluorodeoxyglucose PET (FDG-PET) have high sensitivity and specificity and are of prognostic relevance.78-80 Especially, patients with late gadolinium enhancement detected on CMR are at risk for adverse events, even with preserved left ventricular ejection fraction.81

Radionuclide imaging with gallium 67, thallium 201, technetium, or sestamibi are alternative tests to diagnose and monitor cardiac sarcoidosis that are useful when MRI is contraindicated or not available.82 Nevertheless, due to radiation exposure and associated imaging artifacts that may produce nonspecific results, they have been replaced with CMR and FDG-PET in most centers.82

**Treatment of cardiac sarcoidosis**

Cardiac sarcoidosis mandates rapid treatment, because of the risk of sudden death and progressive heart failure. GCs are the treatment of choice, and no difference in survival rates has been found between higher (>30 mg/day) and lower doses (<30 mg/day) of prednisone.83 A recent systematic review found beneficial effects in the reported literature only for atrioventricular conduction disturbances.84 The body of
evidence is of very limited quality, since controlled trials for cardiac sarcoidosis have not been conducted.

Long-term improvement has been reported with the use of 6 mg MTX weekly in addition to prednisone versus prednisone alone. Ejection fraction and N-terminal prohormone brain natriuretic peptide levels were significantly better with combination therapy at 3 years, but not at 5 years.\(^\text{85}\)

Other alternative treatments, including MTX, CYC and CsA, have been studied retrospectively, and resulted in improvement or recovery in ten of eleven patients with cardiac sarcoidosis.\(^\text{96}\) Infliximab has been reported as an effective therapy for cardiac sarcoidosis in case studies.\(^\text{87,88}\) TNFα blockers are, however, contraindicated in patients with advanced heart failure (New York Heart Association III or IV), as they may worsen symptoms.

Antiarrhythmic therapies have not been studied systematically, and firm recommendations cannot be made based on the available evidence. Amiodarone or sotalol are sometimes used.\(^\text{89}\) Sudden cardiac death can be prevented by ICDs, and approximately a third of patients with ICDs receive appropriate therapies for ventricular arrhythmias.\(^\text{89}\) The expert-consensus statement on management of arrhythmias associated with sarcoidosis by the Heart Rhythm Society\(^\text{90}\) recommends ICD implantation in patients with: 1) spontaneous sustained ventricular arrhythmias, including prior cardiac arrest, and/or 2) left ventricular ejection fraction <35% despite optimal medical therapy and a period of immunosuppression (if there is active inflammation).\(^\text{90}\)

Ultimately, heart transplantation may be considered when all other therapies have failed, apparently without increased complications.\(^\text{91,92}\) Recurrence of sarcoidosis in the allograft has been reported, but seems to be rare.\(^\text{93}\)

Gastrointestinal and hepatic sarcoidosis

Gastrointestinal sarcoidosis is very rare, accounting for only 0%–3.4% of cases, based on autopsy studies. By contrast, autopsy frequently shows hepatic involvement in as many as 80%, depending on the series.\(^\text{94}\) However, asymptomatic elevation in liver-function tests in the context of known sarcoidosis is the most common presentation in approximately a third of patients, and occurs more frequently in African-Americans than in Caucasians.\(^\text{95}\) Of note, alkaline phosphatase seems to be more consistently elevated than aminotransferases in patients with hepatic sarcoidosis.\(^\text{95}\) Clinical manifestations include hepatomegaly, fatigue, right upper-quadrant abdominal pain with pruritus (5%–15%), fever, jaundice, and weight loss (less than 5%).\(^\text{10}\) Rare complications include Budd–Chiari syndrome or hilar lymphadenopathy, cholesterol liver disease mimicking primary biliary cirrhosis, primary sclerosing cholangitis, or obstructive jaundice.\(^\text{96,97}\)

Splenic involvement is most often detected by imaging rather than symptoms or laboratory abnormalities, and has been reported with similar frequency as hepatic involvement. It may present with constitutional symptoms and marked splenomegaly in up to 6% of cases.\(^\text{98,99}\)

Overt gastric or intestinal sarcoidosis presents with fullness, weight loss, protein-losing enteropathy, and signs of obstruction or gastrointestinal bleeding, findings also seen in Crohn’s disease.\(^\text{100,101}\) It is thus important to rule out other common granulomatous disorders that affect the intestines, as both have been reported to coexist in rare cases.\(^\text{102,103}\)

A diagnosis of gastrointestinal or hepatosplenic involvement can be made by endoscopy, computed tomography, or ultrasound with or without contrast media and subsequent biopsy.\(^\text{104–106}\) Abdominal computed tomography shows hepatomegaly or nodules, and ultrasonography can reveal hypo- or hyperechoic nodules when compared to the liver parenchyma.\(^\text{106}\) Noncaseating granulomas of the liver are present in up to 65% of patients in systemic sarcoidosis, and other causes, such as tuberculosis, fungal, or other infections, and drug toxicity, should be excluded.\(^\text{107}\)

Treatment of gastrointestinal sarcoidosis

Asymptomatic hepatic and splenic sarcoidosis does not require treatment. However, in symptomatic patients, GCs can reduce liver and spleen size and number of granulomas and improve organ function to some extent. Nevertheless, the effect on disease course and development of portal hypertension or hepatic fibrosis is limited.\(^\text{108}\) Steroid-sparing agents have been used with some success, and agents such as MTX, AZA, antimalarials, and ursodeoxycholic acid all have been used.\(^\text{109}\) The latter has been used in patients presenting with signs of cholestatic jaundice.\(^\text{110,111}\) AZA is preferred over MTX, AZA, antimalarials, and ursodeoxycholic acid all have been used.\(^\text{109}\) The latter has been used in patients presenting with signs of cholestatic jaundice.\(^\text{110,111}\) AZA is preferred over MTX by some, although both are potentially hepatotoxic.\(^\text{107}\)

In end-stage liver disease, orthotopic liver transplantation has been successfully used as a treatment modality. Recurrences may occur in the allograft,\(^\text{112}\) and allograft-survival rates have been reported to be comparable with other diseases (86% after 5 years).\(^\text{113}\) Another study showed significantly lower rates compared to patients transplanted for primary sclerosing cholangitis or primary biliary cirrhosis (5-year graft-survival rates of 60% versus 75%).\(^\text{114}\)
Musculoskeletal sarcoidosis

Musculoskeletal sarcoidosis is reported in approximately 15%–25% of cases. From a clinical perspective, differentiation of arthritis in acute/chronic and peripheral/axial types seems most useful. Acute arthritis in the context of sarcoidosis most frequently arises in Løfgren’s syndrome (bilateral hilar adenopathy, EN, and bilateral ankle swelling). Ultrasound-based studies have revealed that true arthritis of the ankles is the exception, and swelling is predominantly due to soft-tissue swelling and tenosynovitis. This has been confirmed in a small case series using MRI. The presence of three of four criteria – 1) symmetrical ankle arthritis, 2) symptoms less than 2 months, 3) age below 40 years, and 4) EN reaching sensitivity and specificity of 93% and 99%, respectively – is used for diagnosing acute arthritis related to sarcoidosis.

Chronic sarcoidosis arthritis can mimic other forms of inflammatory arthritis; dactylitis, a feature typical of psoriatic arthritis and other seronegative spondylarthropathies, may also occur in sarcoidosis. Conventional radiographs show a reticular, lacy pattern of the phalanges with singular or numerous cystic lesions, and in some cases, acrocystolysis may be observed and “punched-out lesions” due to granulomatous inflammations can occur. A comprehensive assessment to differentiate other possible causes of arthritis is necessary, since sarcoidosis and other inflammatory diseases may simultaneously be present.

Axial sarcoidosis can involve the vertebral bodies or the sacroiliac joints. The frequency of sacroilitis, the hallmark of seronegative spondylarthropathies, ranges from 6.6% to 14.3% in the literature, and it may not always be possible to distinguish these two entities. A negative human leukocyte antigen B27, however, would favor a diagnosis of sarcoidosis, especially when other sarcoidosis features are present.

Imaging is an important tool for the evaluation of musculoskeletal sarcoidosis. Conventional radiographs are typically the first method. To detect inflammatory changes, ultrasound may be used, but this has mostly been studied in the context of Løfgren’s syndrome. Other, potentially useful tests include MRI and FDG-PET. When vertebral sarcoidosis is suspected and no other features of sarcoidosis are present, a histopathological confirmation is mandatory to exclude other possible causes, especially malignancy or tuberculosis, as these cannot be differentiated with imaging alone.

Treatment of musculoskeletal sarcoidosis

For the acute (peri)arthritis seen in Løfgren’s syndrome, nonsteroidal analgesics may be all that is necessary, but up to two-thirds of patients will nevertheless require additional treatment with GCs. However, the chances of complete remission after a few weeks to months are very high in Løfgren’s syndrome.

Chronic arthritis may or may not be controlled with GCs alone. If GCs fail to control the symptoms, antimalarials and disease-modifying antisarcoid drugs have both been used with success, but controlled clinical trials for sarcoidosis arthritis have not been conducted. MTX is typically the preferred agent for these patients. In severe cases, TNFα antagonists, such as infliximab or adalimumab, may also be used. A management algorithm for patients unresponsive or intolerant to GCs has been proposed.

Conclusion

Extrapulmonary involvement is often underdiagnosed ante-mortem, but can be life-threatening if CNS or cardiac sarcoidosis occur. Subclinical involvement is common, making history-taking and a standardized review of systems essential. Diagnostic tests and appropriate imaging should be guided by history and clinical findings, and biopsies performed if necessary to exclude other causes of organ dysfunction.

The majority of patients will have either spontaneous remission or resolution within 1–2 years. However, up to a third of cases relapse, remain unresponsive, or progress despite treatment with GCs. These cases are considered to have refractory or chronic sarcoidosis. Guidelines are available for many of the manifestations, but firm treatment recommendations cannot be made, due to the lack of high-quality studies. Our suggested treatment approach for various extrapulmonary manifestations of sarcoidosis is depicted in Figure 2.

Adding or initiating disease-modifying antisarcoïd drugs is necessary for many manifestations, and MTX is usually the first agent used by most sarcoidosis experts. Third-line or experimental therapies may be considered if other options fail. Ultimately, organ transplantation is a viable option for cardiac, renal, and liver sarcoidosis unresponsive to medical therapy, and outcomes seem to be comparable to other allograft recipients.
Managing extrapulmonary sarcoidosis

Figure 2 Proposed management algorithm for extrapulmonary manifestations of sarcoidosis.

Note: “?” indicates “conflicting data.”

Abbreviations: ADA, adalimumab; AZA, azathioprine; CNS, central nervous system; CsA, cyclosporine A; CYC, cyclophosphamide; eSRD, end-stage renal disease; GCs, glucocorticoids; HCQ, hydroxychloroquine; HTx, heart transplantation; ICD, implantable cardioverter defibrillator; INF, infliximab; LTx, liver transplantation; MMF, mycophenolate mofetil; MTX, methotrexate; RTx, renal transplantation; THA, thalidomide; UDC, ursodeoxycholic acid; NSAID, non-steroidal anti-inflammatory drugs.

Acknowledgment

The work was supported by a grant from the Bernie Mac Foundation.

Disclosure

The authors report no conflicts of interest in this work.

References


